Division of Advanced Surgical Science and Technology, Graduate School of Medicine, Tohoku University, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan.
World J Surg Oncol. 2013 Mar 1;11:51. doi: 10.1186/1477-7819-11-51.
CD133 was recently reported to be a cancer stem cell marker and a prognostic marker for several tumors. However, few studies have investigated CD133 expression in esophageal squamous cell carcinoma (ESCC). Therefore, we examined whether CD133 could serve as a prognostic marker of ESCC and investigated the correlation between CD133 expression and the clinicopathological findings of ESCC patients and several markers.
We studied 86 ESCC patients who underwent curative surgery without neoadjuvant treatment at Tohoku University Hospital (Sendai, Japan) between January 2000 and December 2005. We analyzed tissue specimens by immunohistochemical staining for CD133, p53, p16, p27, murine double minute 2 (MDM2), Ki-67, and epidermal growth factor receptor (EGFR).
Pathological tumor depth and tumor stage were significantly more advanced among CD133-negative patients than among CD133-positive patients. A log-rank test showed that CD133 immunoreactivity was significantly correlated with the overall survival of the patients (P = 0.049). However, multivariate analysis showed that it was not significantly correlated (P = 0.078). Moreover, CD133 was significantly positively correlated with p27 immunoreactivity (P = 0.0013) and tended to be positively correlated with p16 immunoreactivity (P = 0.057). In addition, p16 immunoreactivity was correlated with smoking history (P = 0.018), pathological lymph node status (P = 0.033), and lymphatic invasion (P = 0.018).
This study indicated that CD133 immunoreactivity is a good predictor of prognosis in ESCC patients. In addition, CD133 may play a role in the regulation of tumor cell cycle through p27 and p16 in ESCC. At present, it thus remains controversial whether CD133 expression is a valid prognostic marker for ESCC. To elucidate this relationship, further investigations are required.
CD133 最近被报道为几种肿瘤的癌症干细胞标志物和预后标志物。然而，很少有研究调查 CD133 在食管鳞状细胞癌 (ESCC) 中的表达。因此，我们研究了 CD133 是否可以作为 ESCC 的预后标志物，并研究了 CD133 表达与 ESCC 患者的临床病理发现和几种标志物之间的相关性。
我们研究了 2000 年 1 月至 2005 年 12 月在日本东北大学医院 (仙台) 接受根治性手术且无新辅助治疗的 86 例 ESCC 患者的组织标本。我们通过免疫组织化学染色分析 CD133、p53、p16、p27、鼠双微体 2 (MDM2)、Ki-67 和表皮生长因子受体 (EGFR)。
CD133 阴性患者的病理肿瘤深度和肿瘤分期明显比 CD133 阳性患者更晚。对数秩检验表明，CD133 免疫反应性与患者的总生存率显著相关 (P = 0.049)。然而，多变量分析表明，它与总生存率无显著相关性 (P = 0.078)。此外，CD133 与 p27 免疫反应性显著正相关 (P = 0.0013)，且与 p16 免疫反应性呈正相关趋势 (P = 0.057)。此外，p16 免疫反应性与吸烟史 (P = 0.018)、病理淋巴结状态 (P = 0.033) 和淋巴管浸润 (P = 0.018) 相关。
本研究表明，CD133 免疫反应性是 ESCC 患者预后的良好预测指标。此外，CD133 可能通过 ESCC 中的 p27 和 p16 调节肿瘤细胞周期。目前，CD133 表达是否是 ESCC 的有效预后标志物仍存在争议。为了阐明这种关系，需要进一步的研究。
